Fibrogen Inc FGEN
We take great care to ensure that the data presented and summarized in this overview for FIBROGEN INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FGEN
View all-
Primecap Management CO Pasadena, CA9.91MShares$3.27 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.8MShares$2.24 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.88MShares$1.94 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.91MShares$1.29 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.41MShares$795,1840.0% of portfolio
-
683 Capital Management, LLC New York, NY2.14MShares$705,6720.08% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ2.11MShares$695,8190.0% of portfolio
-
Jpmorgan Chase & CO New York, NY1.67MShares$552,2730.0% of portfolio
-
Marshall Wace, LLP London, X01.44MShares$476,7970.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V81.37MShares$453,7320.0% of portfolio
Latest Institutional Activity in FGEN
Top Purchases
Top Sells
About FGEN
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Transactions at FGEN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 07
2024
|
Juan Graham CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,065
-0.63%
|
$0
$0.39 P/Share
|
|
Sep 06
2024
|
Christine Chung SVP, CHINA OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
17,395
-5.41%
|
$0
$0.39 P/Share
|
|
Sep 06
2024
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,363
-0.56%
|
$0
$0.39 P/Share
|
|
Sep 06
2024
|
Juan Graham CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
16,050
-8.7%
|
$0
$0.39 P/Share
|
|
Aug 01
2024
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,840
-4.68%
|
$0
$0.47 P/Share
|
|
Jun 22
2024
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
782
-0.18%
|
$782
$1.13 P/Share
|
|
Jun 12
2024
|
Deyaa Adib Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
22,123
+21.22%
|
$22,123
$1.17 P/Share
|
|
Jun 07
2024
|
Juan Graham CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,182
-0.64%
|
$1,182
$1.1 P/Share
|
|
Jun 06
2024
|
Juan Graham CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
17,797
-8.75%
|
$17,797
$1.19 P/Share
|
|
Jun 06
2024
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,255
-0.5%
|
$2,255
$1.19 P/Share
|
|
Jun 06
2024
|
Christine Chung SVP, CHINA OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
19,289
-5.66%
|
$19,289
$1.19 P/Share
|
|
May 01
2024
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,840
-4.44%
|
$20,840
$1.17 P/Share
|
|
Mar 22
2024
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
782
-0.17%
|
$1,564
$2.58 P/Share
|
|
Mar 07
2024
|
Thane Wettig CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+9.61%
|
$50,000
$1.91 P/Share
|
|
Mar 07
2024
|
Juan Graham CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,181
-0.58%
|
$1,181
$1.79 P/Share
|
|
Mar 06
2024
|
Juan Graham CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
20,749
-4.63%
|
$20,749
$1.87 P/Share
|
|
Mar 06
2024
|
Juan Graham CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
781
+0.38%
|
-
|
|
Mar 06
2024
|
Christine Chung SVP, CHINA OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
23,590
-3.25%
|
$23,590
$1.87 P/Share
|
|
Mar 06
2024
|
Christine Chung SVP, CHINA OPERATIONS |
BUY
Grant, award, or other acquisition
|
Direct |
781
+0.23%
|
-
|
|
Mar 06
2024
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,535
-0.54%
|
$4,535
$1.87 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 249K shares |
|---|---|
| Open market or private purchase | 72.1K shares |
| Payment of exercise price or tax liability | 232K shares |
|---|